A Pharmacokinetics, Pharmacodynamics and Safety study of CAM2029 for the treatment of acromegaly, neuroendocrine tumors (NETs).

Trial Profile

A Pharmacokinetics, Pharmacodynamics and Safety study of CAM2029 for the treatment of acromegaly, neuroendocrine tumors (NETs).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Neuroendocrine tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 06 May 2016 Planned End Date changed to 1 Jul 2012.
    • 06 May 2016 New trial record
    • 13 Nov 2011 According to a Camurus media release, the company expects to completed and reported by the third quarter of 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top